title: Comparative evaluation of in vitro parameters of tamoxifen citrate loaded poly(lactide-co-glycolide), poly(epsilon-caprolactone) and chitosan nanoparticles.
abstract: Tamoxifen (TAM), the clinical choice for the antiestrogen treatment of advanced or metastatic breast cancer, was formulated in nanoparticulate carrier systems in the form of poly(lactide-co-glycolide) (PLGA), poly-epsilon-caprolactone (PCL) and chitosan (CS) nanoparticles. The PLGA and PCL nanoparticles were prepared by a nanoprecipitation technique whereas the CS nanoparticles were prepared by the ionic gelation method. Mean particle sizes were under 260 nm for PLGA and PCL nanoparticles and around 400 nm for CS nanoparticles. Polydispersity indices were less than 0.4 for all formulations. Zeta potential values were positive for TAM loaded nanoparticles because of the positive charge of the drug. Drug loading values were significantly higher for PCL nanoparticles when compared to PLGA and CS nanoparticles. All nanoparticle formulations exhibited controlled release properties. These results indicate that TAM loaded PLGA, PCL and CS nanoparticles may provide promising carrier systems for tumor targeting.
authors.affiliation: Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
authors.forename: Y
authors.initials: Y
authors.lastname: Cirpanli
authors.forename: F
authors.initials: F
authors.lastname: Yerlikaya
authors.forename: K
authors.initials: K
authors.lastname: Ozturk
authors.forename: N
authors.initials: N
authors.lastname: Erdogar
authors.forename: M
authors.initials: M
authors.lastname: Launay
authors.forename: C
authors.initials: C
authors.lastname: Gegu
authors.forename: T
authors.initials: T
authors.lastname: Leturgez
authors.forename: E
authors.initials: E
authors.lastname: Bilensoy
authors.forename: S
authors.initials: S
authors.lastname: Calis
authors.forename: Y
authors.initials: Y
authors.lastname: Capan
mesh_terms: D001682:Biological Availability; D048271:Chitosan; D002851:Chromatography, High Pressure Liquid; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004563:Electrochemistry; D004965:Estrogen Antagonists / Q000008:administration & dosage* / Q000737:chemistry; D005079:Excipients; D019344:Lactic Acid; D008855:Microscopy, Electron, Scanning; D053758:Nanoparticles; D010316:Particle Size; D011091:Polyesters; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013629:Tamoxifen / Q000008:administration & dosage* / Q000737:chemistry
chemical_list: D004965:Estrogen Antagonists; D005079:Excipients; D011091:Polyesters; D013629:Tamoxifen; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; C016240:polycaprolactone; D011100:Polyglycolic Acid; D019344:Lactic Acid; D048271:Chitosan